Literature DB >> 15803169

Resting pulse rates in a glaucoma clinic: the effect of topical and systemic beta-blocker usage.

C Tattersall1, S Vernon, R Singh.   

Abstract

INTRODUCTION: Beta-blockers have, for 25 years, been a commonly used agent in the treatment of raised intraocular pressure (IOP). Beta-blockers can also reduce the pulse rate. With no available literature examining a cohort of patients, this study aims to investigate the resting pulse rates in patients attending a specialist glaucoma clinic in order to identify if routine review of ophthalmic medication use is indicated.
METHOD: The resting pulse rates of patients attending a glaucoma clinic were measured using pulseoximetry, with a medical and drug history established for each patient.
RESULTS: In all, 205 patients were included in the study. A total of 101 (49%) of patients were using beta-blockers in some form. The mean pulse rate for patients not using beta-blockers (104 patients) was 76 beats per minute (bpm), for topical use only (68 patients) it was 70.3 bpm, for oral use (18 patients) it was 64.7 bpm, and 58 bpm for patients using both topical and oral beta-blockers (15 patients). Groups using beta-blockers (oral, topical, oral and topical) were considered in relation to patients not using beta-blockers. All groups using beta-blockers showed a significant association with causing a bradycardia of less than 60 bpm. Patients with a pulse rate of less than 50 bpm were significantly more likely to be using topical and oral beta-blockers than oral beta-blockers alone (P=0.01).
CONCLUSION: Topical beta-blockers should be used with caution, even in the presence of established systemic beta-blocker use. Routine pulse rate monitoring and review of ophthalmic medication are indicated in patients using beta-blocker therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 15803169     DOI: 10.1038/sj.eye.6701859

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  7 in total

1.  Using Esterase Selectivity to Determine the In Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-Blockers.

Authors:  Jillian G Baker; Christophe Fromont; Marjorie Bruder; Kevin S J Thompson; Barrie Kellam; Stephen J Hill; Sheila M Gardiner; Peter M Fischer
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-01

2.  Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy.

Authors:  Kenji Kashiwagi
Journal:  Jpn J Ophthalmol       Date:  2012-05-15       Impact factor: 2.447

3.  Sick sinus syndrome associated with topical timolol maleate instillation.

Authors:  Harpreet S Walia; Sandeep S Walia; Matthew E Emanuel
Journal:  J Pharmacol Pharmacother       Date:  2011-10

4.  Bradyarrhythmias secondary to topical levobunolol hydrochloride solution.

Authors:  Lianjun Lin; Yuchuan Wang; Yan Chen; Meilin Liu
Journal:  Clin Interv Aging       Date:  2014-10-13       Impact factor: 4.458

5.  Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy.

Authors:  Kazuyoshi Kitamura; Tatsuya Chiba; Fumihiko Mabuchi; Kiyotaka Ishijima; Shu Omoto; Fumiko Kashiwagi; Takashi Godo; Satoshi Kogure; Teruhiko Goto; Takashi Shibuya; Jhoji Tanabe; Shigeo Tsukahara; Tadaharu Tsuchiya; Toyoaki Tsumura; Takaharu Tokunaga; Osamu Hosaka; Tetsunori Saito; Kenji Kashiwagi
Journal:  J Ophthalmol       Date:  2018-02-21       Impact factor: 1.909

6.  Management and outcome of topical beta-blocker-induced atrioventricular block.

Authors:  Kazim Serhan Özcan; Bariş Güngör; Damirbek Osmonov; Ahmet Ilker Tekkeşin; Servet Altay; Ahmet Ekmekçi; Ercan Toprak; Ersin Yildirim; Nazmi Çalik; Ahmet Taha Alper; Kadir Gürkan; Izzet Erdinler
Journal:  Cardiovasc J Afr       Date:  2015 Nov-Dec       Impact factor: 1.167

Review 7.  Complete atrioventricular block due to timolol eye drops: a case report and literature review.

Authors:  Zhuoying Wang; Ian Denys; Feng Chen; Lijie Cai; Xuecui Wang; Daniel R Kapusta; Yongliang Lv; Juan Gao
Journal:  BMC Pharmacol Toxicol       Date:  2019-12-02       Impact factor: 2.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.